Mutual of America Capital Management LLC Sells 313 Shares of Charles River Laboratories International, Inc. $CRL

Mutual of America Capital Management LLC decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 5,625 shares of the medical research company’s stock after selling 313 shares during the period. Mutual of America Capital Management LLC’s holdings in Charles River Laboratories International were worth $853,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Teacher Retirement System of Texas acquired a new stake in shares of Charles River Laboratories International during the first quarter worth $1,231,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Charles River Laboratories International by 15.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company’s stock worth $952,000 after buying an additional 817 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Charles River Laboratories International by 61.6% during the 1st quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company’s stock worth $210,000 after buying an additional 533 shares during the period. Concurrent Investment Advisors LLC acquired a new position in shares of Charles River Laboratories International during the 1st quarter worth about $213,000. Finally, GW&K Investment Management LLC increased its stake in shares of Charles River Laboratories International by 41.1% in the 1st quarter. GW&K Investment Management LLC now owns 88,410 shares of the medical research company’s stock valued at $13,307,000 after acquiring an additional 25,744 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the completion of the transaction, the executive vice president owned 24,116 shares in the company, valued at $3,800,681.60. This trade represents a 3.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Trading Down 0.8%

NYSE:CRL opened at $195.45 on Tuesday. The company has a market cap of $9.62 billion, a P/E ratio of -146.96, a price-to-earnings-growth ratio of 5.28 and a beta of 1.50. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $230.02. The business has a 50 day moving average price of $165.19 and a two-hundred day moving average price of $150.77. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. During the same quarter in the previous year, the firm posted $2.80 earnings per share. The firm’s revenue for the quarter was up .6% on a year-over-year basis. As a group, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on CRL shares. JPMorgan Chase & Co. boosted their price objective on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research report on Monday, October 6th. Mizuho boosted their price target on shares of Charles River Laboratories International from $155.00 to $174.00 and gave the company a “neutral” rating in a report on Friday, October 17th. Citigroup raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. Eight equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $181.29.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).